ROCKVILLE, Md., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE
Amex:GTF), a leading developer of biologically active regenerative therapies for
wound care, inflammation and angiogenesis, today announced that Martin
Rosendale, Chief Executive Officer of Cytomedix, will be presenting a corporate
update at the 8th Annual BIO Investor Forum on Thursday, October 29th at 2:30
p.m. (Pacific Time) at the Palace Hotel in San Francisco, California.
A live audio link to the webcast presentation is available on the company's
website at www.cytomedix.com. It is recommended that listeners log on 15 minutes
in advance of the presentation to register and download any necessary software.
An audio replay will be accessible approximately one hour following the
presentation and will be archived for 90 days on the Cytomedix website.
About Bio Investor Forum
The Bio Investor Forum, sponsored by the Biotechnology Industry Organization
(BIO), is a national investor forum to explore investment trends and
opportunities in life sciences, with a focus on public and venture-stage growth
companies as well as those poised to join the growth "watch list" in 2010. This
forum is attended by public and private equity investors, research analysts,
investment bankers and industry executives focused on investment and business
development opportunities in the life sciences.
BIO represents more than 1,200 biotechnology companies, academic institutions,
state biotechnology centers and related organizations across the United States
and in more than 30 other nations. BIO members are involved in the research and
development of innovative healthcare, agricultural, industrial and environmental
biotechnology technologies. BIO also produces the annual BIO International
Convention, the world's largest gathering of the biotechnology industry, along
with industry- leading innovator and partnering meetings held around the world.
About Cytomedix
Cytomedix develops, sells and licenses regenerative biological therapies
including the AutoloGel System, a device for the production of Platelet Rich
Plasma ("PRP") gel derived from the patient's own blood. The AutoloGel System is
cleared by the U.S. Food and Drug Administration for use on a variety of exuding
wounds. The Company is pursuing a multi-faceted strategy to penetrate the
chronic wound market with its AutoloGel System. The Company is also moving
forward with the development of other product candidates in its pipeline. Most
notably is its CT-112 product, an anti-inflammatory peptide that has shown
promise in preclinical testing. Additional information regarding Cytomedix is
available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are
forward-looking statements that are intended to fall within the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, viability and effectiveness of the Company's sales
approach and overall marketing strategies, the outcome of development or
regulatory review of CT-112, commercial success or acceptance by the medical
community, competitive responses, the Company's ability to raise additional
capital and to continue as a going concern, its ability to successfully
commercialize its product in Japan under the terms of the license agreement, and
Cytomedix's ability to execute on its strategy to market the AutoloGel(tm)
System as contemplated. These forward-looking statements are subject to known
and unknown risks and uncertainties that could cause actual events to differ
from the forward-looking statements. More information about some of these risks
and uncertainties may be found in the reports filed with the Securities and
Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly
competitive and rapidly changing business and regulatory environment, thus new
or unforeseen risks may arise. Accordingly, investors should not place any
reliance on forward-looking statements as a prediction of actual results. Except
as is expressly required by the federal securities laws, Cytomedix undertakes no
obligation to update or revise any forward-looking statements, whether as a
result of new information, changed circumstances or future events or for any
other reason.
-0-
CONTACT: Cytomedix, Inc.
David Jorden, Executive Board Member
Martin Rosendale, CEO
(240) 499-2680
Lippert/Heilshorn & Associates
Anne Marie Fields
(212) 838-3777
afields@lhai.com
